Pancreatic Cancer Research

ResearcherJapan Community Healthcare OrganizationActive in the last 2 years

Hideaki Shimada

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-1990-8217; OpenAlex author ID A5059882010, A5061343194, A5111794795, A5128016019. Sources: OpenAlex.

Their work

Papers
7 (first author 0, last author 4)
Trials
0
Grants
0
Labs led
1
Collaborators
34
Papers, trials and grants by year

2014: 1 paper · 2015: none · 2016: none · 2017: none · 2018: 1 paper · 2019: none · 2020: 1 paper · 2021: none · 2022: 1 paper · 2023: none · 2024: none · 2025: 1 paper · 2026: 2 papers

Papers 7

  1. Preoperative low C-reactive protein-albumin-lymphocyte (CALLY) index is a poor prognostic indicator for overall survival in patients undergoing surgery for pan… Last author DOI 10.1007/s00595-026-03270-8↗
  2. Prognostic and diagnostic significance of serum p53 antibody levels in patients with surgically treated pancreatic cancer. Last author DOI 10.3892/ol.2026.15560↗
  3. Low prealbumin level is a poor prognostic biomarker for surgically treated pancreatic cancer. Last author DOI 10.3892/mco.2025.2856↗
  4. Synopsis of a clinical practice guideline for pancreatic ductal adenocarcinoma with peritoneal dissemination in Japan; Japan Peritoneal Malignancy Study Group. Co-author DOI 10.1002/jhbp.1085↗
  5. Are preoperative high soluble programmed death ligand 1 levels responsible for patients’ poor prognoses in hepato-biliary-pancreatic cancer? Last author DOI 10.21203/rs.3.rs-52812/v2↗
  6. Combination Gemcitabine and WT1 Peptide Vaccination Improves Progression-Free Survival in Advanced Pancreatic Ductal Adenocarcinoma: A Phase II Randomized Stud… Co-author DOI 10.1158/2326-6066.cir-17-0386↗
  7. [An analysis of cases with malignant pyloroduodenal obstruction from unresectable pancreatic cancer who underwent palliative gastrojejunostomy]. Co-author PMID 25731475↗

Closest collaborators

The 25 strongest of 34 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Yu Matsumoto · 3 shared papers, 2025–2026 · strength 0.92
  2. Rei Okada · 3 shared papers, 2020–2026 · strength 0.67
  3. Tetsuya Maeda · 3 shared papers, 2014–2025 · strength 0.40
  4. 嶺 岡田 · 1 shared paper, 2026 · strength 0.36
  5. Hironori Kaneko · 2 shared papers, 2014–2020 · strength 0.15
  6. So Yamaki · 1 shared paper, 2022 · strength 0.12
  7. Sohei Satoi · 1 shared paper, 2022 · strength 0.12
  8. Masamichi Hayashi · 1 shared paper, 2022 · strength 0.12
  9. Suguru Yamada · 1 shared paper, 2022 · strength 0.12
  10. Naminatsu Takahara · 1 shared paper, 2022 · strength 0.12
  11. Hiroyuki Isayama · 1 shared paper, 2022 · strength 0.12
  12. Joji Kitayama · 1 shared paper, 2022 · strength 0.12
  13. Daisuke Hashimoto · 1 shared paper, 2022 · strength 0.12
  14. Tomohisa Yamamoto · 1 shared paper, 2022 · strength 0.12
  15. Hironori Yamaguchi · 1 shared paper, 2022 · strength 0.12
  16. Kei Saito · 1 shared paper, 2022 · strength 0.12
  17. Yousuke Nakai · 1 shared paper, 2022 · strength 0.12
  18. Tsutomu Fujii · 1 shared paper, 2022 · strength 0.12
  19. Masanori Kon · 1 shared paper, 2018 · strength 0.06
  20. Hiroaki Yanagimoto · 1 shared paper, 2018 · strength 0.06
  21. Mari S. Oba · 1 shared paper, 2018 · strength 0.06
  22. Kei Ito · 1 shared paper, 2018 · strength 0.06
  23. Shinichi Egawa · 1 shared paper, 2018 · strength 0.06
  24. Yoshihide Kanno · 1 shared paper, 2018 · strength 0.06
  25. Hidetoshi Eguchi · 1 shared paper, 2018 · strength 0.06

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.